Clinical Trial: Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+
Brief Summary: The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%. In recent years, Tyrosine Kinase Inhibitor(TKI) has improved outcome of Philadelphia chromosome positive (Ph+)ALL . But in some high risk groups, The prognosis of patients is still very bad and the relapse rate is high. Clearly, new therapies are urgently needed to prevent and /or treat relapsed ALL.
Detailed Summary:
- The prognosis of childhood acute lymphoblastic leukemia(ALL) has been increased.
- Tyrosine Kinase Inhibitor(TKI) has improved Philadelphia chromosome positive (Ph+)ALL treatment outcome.
- The prognosis of high-risk childhood ALL except for Philadelphia chromosome positive (Ph+)ALL is very bad.
Sponsor: Chinese Academy of Medical Sciences
Current Primary Outcome: The event free survival of high risk ALL [ Time Frame: 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome: The relapsed rate, death, overall survival [ Time Frame: 2 years ]
Original Secondary Outcome: Same as current
Information By: Chinese Academy of Medical Sciences
Dates:
Date Received: November 16, 2013
Date Started: October 2012
Date Completion: October 2014
Last Updated: November 20, 2013
Last Verified: November 2013
